News | October 02, 2024
Sun Pharma and Philogen enter into a exclusive commercialization and supply agreement for Fibromun
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the United States and Europe markets in the year 2022
NUBEQA is currently indicated for the treatment of adult patients with mHSPC in combination with docetaxel and for non-metastatic castration-resistant prostate cancer (nmCRPC)
Agreement enables access of EU-approved treatment for myotonia symptoms in non-dystrophic myotonic disorders to patients from Argentina and Colombia
India called for stronger investments in health and social equity at G20 Joint Finance-Health Task Force Meeting
Quinidine Sulphate helps manage rare irregular heartbeat conditions
Pfizer's decision is based on the totality of clinical data
This approval reflects company’s unwavering commitment that the quality assurance
The raised capital enables Medix Biochemica to continue execution of inorganic growth initiatives
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
